l-dopa


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to l-dopa: levodopa, dopamine, Mucuna pruriens

dopa

 [do´pah]
a compound produced by oxidation of tyrosine by tyrosinase; it is the precursor of dopamine and an intermediate product in the biosynthesis of norepinephrine, epinephrine, and melanin. The naturally occurring form is l-dopa (see levodopa), and is used to treat parkinson's disease and other forms of parkinsonism.

le·vo·do·pa

(lē'vō-dō'pă),
The biologically active form of dopa; an antiparkinsonian agent that is converted to dopamine.
Synonym(s): l-dopa

L-dopa

(ĕl-dō′pə)
n.
An isomer of dopa that is converted in the brain to dopamine and is used in synthetic form to treat Parkinson's disease. Also called levodopa.

l-dopa

Abbreviation for levodopa.

Levodopa (L-dopa)

A substance used in the treatment of Parkinson's disease. Levodopa can cross the blood-brain barrier that protects the brain. Once in the brain, it is converted to dopamine and thus can replace the dopamine lost in Parkinson's disease.
Mentioned in: Movement Disorders
References in periodicals archive ?
Since the introduction of L-dopa in the late 1960s, researchers have known that the body's enzymes (tools that perform necessary chemistry) can break down L-dopa in the gut, preventing the drug from reaching the brain.
To test whether the primary anti-DOPA antibody specifically binds L-DOPA, we used a strategy of pre-incubating pure L-DOPA antigen with the primary antibody prior to introducing this mixture to the fixed tissue, as in the standard protocol described above.
Conclusion: L-dopa is an effective treatment for bringing positive personality and cognition related changes in patients with idiopathic PD.
In Pakistan, PD patients are given L-dopa as a mono-therapy or with combination of other pharmacological agents such as benserzide, anticholinergics etc.6 A recent study with Pakistani population showed high prevalence of cognitive deficits in patients with PD.7 Few studies have shown L-dopa beneficial effects on motor function, alertness, cognitive and neuropsychological performance of patients with PD.8,9 There is a missing link in previous literature about L-dopa response to cortical functioning, health related quality of life and fatigue severity in patients with I-PD.
6-OHDA lesioned rats which had severe dopaminergic denervation-treated with L-dopa (Complete/L-dopa) (n=6)
Then a 120 [micro]L of an L-dopa solution (0.0625 to 0.25 mM) in a sodium phosphate buffer (pH 6.8) was added to initiate the reaction.
Among the central dopaminergic side effects of L-dopa, hallucinations and psychotic symptoms can cause important problems.
During L-DOPA treatment, body weights were recorded weekly till the end of the experiment for all the groups.
The effect of fumarprotocetraric acid on L-DOPA oxidation mediated by tyrosinase was evaluated spectrophotometrically (Bioespectro SP220) at 475 nm.
Wang 2002 basal bladder pressure in L-dopa injected group (p < 0.05 versus normal saline injected group).
The substrate was L-dopa by 120 [micro]L 0.1 mM in a sodium phosphate buffer at pH 6.8.
The samples were transferred to and incubated in fresh PBS with 1 mg/ml L-3,4-dihydroxyphenylalanine (l-DOPA; Sigma) for 90 min at 30[degrees]C, and then washed in distilled water (Zhang & Li 2000).